Russell Investments Group Ltd. Trims Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Russell Investments Group Ltd. reduced its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 31.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,649 shares of the specialty pharmaceutical company’s stock after selling 6,223 shares during the quarter. Russell Investments Group Ltd.’s holdings in Collegium Pharmaceutical were worth $391,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the business. Principal Financial Group Inc. increased its position in shares of Collegium Pharmaceutical by 3.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after purchasing an additional 64,958 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Collegium Pharmaceutical by 0.7% during the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company’s stock valued at $29,974,000 after purchasing an additional 5,464 shares during the last quarter. Royce & Associates LP grew its stake in Collegium Pharmaceutical by 11.0% during the 4th quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company’s stock valued at $9,728,000 after acquiring an additional 33,674 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after purchasing an additional 175,892 shares during the last quarter. Finally, Hillsdale Investment Management Inc. boosted its stake in shares of Collegium Pharmaceutical by 1.0% during the 4th quarter. Hillsdale Investment Management Inc. now owns 116,200 shares of the specialty pharmaceutical company’s stock worth $3,329,000 after acquiring an additional 1,100 shares in the last quarter.

Collegium Pharmaceutical Stock Down 3.3 %

NASDAQ COLL opened at $25.99 on Thursday. The business has a fifty day moving average price of $28.51 and a two-hundred day moving average price of $30.96. The stock has a market capitalization of $835.11 million, a PE ratio of 11.20 and a beta of 0.76. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $42.29. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The business had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. Equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 977 shares of Collegium Pharmaceutical stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the sale, the chief financial officer now owns 164,269 shares of the company’s stock, valued at approximately $4,928,070. The trade was a 0.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Scott Dreyer sold 2,255 shares of the business’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the sale, the executive vice president now owns 124,421 shares in the company, valued at $3,732,630. This represents a 1.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,693 shares of company stock valued at $2,334,994. Company insiders own 2.51% of the company’s stock.

Analyst Ratings Changes

COLL has been the subject of several recent research reports. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 19th. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Needham & Company LLC reissued a “buy” rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Finally, Piper Sandler lowered their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.